Stocktoria
Xeris Biopharma Holdings, Inc. XERS
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2018-06-21
Chart by TradingView
7/9
Piotroski F — financial health
-2.99
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $291.8M | $203.1M | $163.9M | $110.2M | $49.6M |
| Operating income | $24.9M | -$33.6M | -$44.0M | -$81.9M | -$115.2M |
| Net income | $554,000 | -$54.8M | -$62.3M | -$94.7M | -$122.7M |
| Operating cash flow | $28.6M | -$37.0M | -$47.0M | -$102.9M | -$95.5M |
| Free cash flow | — | — | — | — | -$96.6M |
| Total assets | $383.5M | $323.1M | $322.6M | $344.5M | $304.4M |
| Total liabilities | $369.8M | $352.7M | $329.4M | $299.3M | $209.1M |
| Shareholders' equity | $13.7M | -$29.6M | -$6.8M | $45.2M | $95.2M |
| Ratios | |||||
| Operating margin | 8.5% | -16.6% | -26.8% | -74.3% | -232.2% |
| Net margin | 0.2% | -27.0% | -38.0% | -85.9% | -247.5% |
| FCF margin | — | — | — | — | -194.8% |
| Return on assets | 0.1% | -17.0% | -19.3% | -27.5% | -40.3% |
| Return on equity | 4.0% | 185.2% | 917.9% | -209.5% | -128.9% |
| Debt / equity | 16.10× | -7.33× | -28.15× | 4.14× | 0.92× |
| Current ratio | 2.19 | 1.67 | 1.64 | 2.54 | 1.80 |
| Revenue growth | 43.7% | 23.9% | 48.7% | 122.3% | 142.7% |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 452,860 | $2.6M |
Why these scores methodology →
Piotroski F-score: 7/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -2.99 (distress)
- Working capital / assets 0.341
- Retained earnings / assets -1.75
- EBIT / assets 0.065
- Equity / liabilities 0.037
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001867096 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.